phosphorylcholine has been researched along with Cancer of Ovary in 12 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "On the basis of reversal of taxane resistance with AKT inhibition, we initiated a phase I trial of the AKT inhibitor perifosine with docetaxel in taxane and platinum-resistant or refractory epithelial ovarian cancer." | 9.16 | Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. ( Atkinson, E; Bast, RC; Coleman, RL; Coombes, KR; Dice, K; Dyer, M; Fu, S; Gershenson, DM; Hennessy, BT; Howard, A; Jackson, E; Ju, Z; Kavanagh, JJ; Kundra, V; Kurzrock, R; Levenback, CF; Li, J; Li, Y; Markman, M; Mills, GB; Ng, CS; Sood, AK; Stemke-Hale, K; Wolf, JK, 2012) |
| "On the basis of reversal of taxane resistance with AKT inhibition, we initiated a phase I trial of the AKT inhibitor perifosine with docetaxel in taxane and platinum-resistant or refractory epithelial ovarian cancer." | 5.16 | Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. ( Atkinson, E; Bast, RC; Coleman, RL; Coombes, KR; Dice, K; Dyer, M; Fu, S; Gershenson, DM; Hennessy, BT; Howard, A; Jackson, E; Ju, Z; Kavanagh, JJ; Kundra, V; Kurzrock, R; Levenback, CF; Li, J; Li, Y; Markman, M; Mills, GB; Ng, CS; Sood, AK; Stemke-Hale, K; Wolf, JK, 2012) |
| " When administered to human ovarian tumor-bearing mice using a recurring dosing regimen comparable to that used clinically, polyMPC-Dox significantly retarded tumor growth relative to treatment with free Dox." | 1.43 | Evaluation of PolyMPC-Dox Prodrugs in a Human Ovarian Tumor Model. ( Arenas, RB; Crisi, GM; Emrick, T; McRae Page, S; Mora, MC; Schneider, SS; Skinner, M; Wong, KE, 2016) |
| "Treatment with perifosine concurrently with cisplatin significantly enhanced the antitumor effect of cisplatin." | 1.42 | Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary. ( Hashimoto, K; Hisamatsu, T; Isobe, A; Kawano, M; Kimura, T; Kuroda, H; Mabuchi, S; Matsumoto, Y; Sasano, T; Sawada, K; Takahashi, R; Testa, JR, 2015) |
| "We recently showed that epithelial ovarian cancer (EOC) possesses an altered MRS-choline profile, characterised by increased phosphocholine (PCho) content to which mainly contribute over-expression and activation of choline kinase-alpha (ChoK-alpha)." | 1.40 | Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer. ( Bagnoli, M; Canevari, S; De Cecco, L; Granata, A; Iorio, E; Mezzanzanica, D; Nicoletti, R; Pisanu, ME; Podo, F; Ricci, A; Tinaglia, V, 2014) |
| "Perifosine-response was associated with the expression (FDR<0." | 1.39 | Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest. ( Abbasi, F; Al Sawah, E; Apte, SM; Bou Zgheib, N; Chen, X; Chon, HS; Judson, PL; Lancaster, JM; Marchion, DC; Ramirez, IJ; Wenham, RM; Xiong, Y, 2013) |
| "Endometrial and ovarian cancer cells were treated with various concentrations of ErPC, and its effect on cell growth, cell cycle, apoptosis, and related measurements was investigated." | 1.35 | Erucylphosphocholine shows a strong anti-growth activity in human endometrial and ovarian cancer cells. ( Narahara, H; Nasu, K; Takai, N; Ueda, T, 2008) |
| "In contrast to malignant ovarian cancer cells, immortalized human ovarian epithelial cells did not respond to any of these lipids to increase the secretion of IL-8, although these cells secreted similar basal levels of IL-8 (310 pg/ml/10,000 cells)." | 1.31 | Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. ( Baudhuin, LM; Hong, G; Mok, SC; Morrison, BH; Schwartz, BM; Wu, W; Xiao, YJ; Xu, Y, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Z | 1 |
| Tan, Y | 1 |
| Li, X | 1 |
| Quan, J | 1 |
| Bode, AM | 1 |
| Cao, Y | 1 |
| Luo, X | 1 |
| Al Sawah, E | 1 |
| Chen, X | 1 |
| Marchion, DC | 1 |
| Xiong, Y | 1 |
| Ramirez, IJ | 1 |
| Abbasi, F | 1 |
| Bou Zgheib, N | 1 |
| Chon, HS | 1 |
| Wenham, RM | 1 |
| Apte, SM | 1 |
| Judson, PL | 1 |
| Lancaster, JM | 1 |
| Granata, A | 1 |
| Nicoletti, R | 1 |
| Tinaglia, V | 1 |
| De Cecco, L | 1 |
| Pisanu, ME | 1 |
| Ricci, A | 1 |
| Podo, F | 2 |
| Canevari, S | 2 |
| Iorio, E | 2 |
| Bagnoli, M | 1 |
| Mezzanzanica, D | 2 |
| Sasano, T | 1 |
| Mabuchi, S | 1 |
| Kuroda, H | 1 |
| Kawano, M | 1 |
| Matsumoto, Y | 1 |
| Takahashi, R | 1 |
| Hisamatsu, T | 1 |
| Sawada, K | 1 |
| Hashimoto, K | 1 |
| Isobe, A | 1 |
| Testa, JR | 1 |
| Kimura, T | 1 |
| Wong, KE | 1 |
| Mora, MC | 1 |
| Skinner, M | 1 |
| McRae Page, S | 1 |
| Crisi, GM | 1 |
| Arenas, RB | 1 |
| Schneider, SS | 1 |
| Emrick, T | 1 |
| Takai, N | 1 |
| Ueda, T | 1 |
| Nasu, K | 1 |
| Narahara, H | 1 |
| Engel, JB | 1 |
| Schönhals, T | 1 |
| Häusler, S | 1 |
| Krockenberger, M | 1 |
| Schmidt, M | 1 |
| Horn, E | 1 |
| Köster, F | 1 |
| Dietl, J | 1 |
| Wischhusen, J | 1 |
| Honig, A | 1 |
| Sun, H | 1 |
| Yu, T | 1 |
| Li, J | 2 |
| Fu, S | 1 |
| Hennessy, BT | 1 |
| Ng, CS | 1 |
| Ju, Z | 1 |
| Coombes, KR | 1 |
| Wolf, JK | 1 |
| Sood, AK | 1 |
| Levenback, CF | 1 |
| Coleman, RL | 1 |
| Kavanagh, JJ | 1 |
| Gershenson, DM | 1 |
| Markman, M | 1 |
| Dice, K | 1 |
| Howard, A | 1 |
| Li, Y | 1 |
| Stemke-Hale, K | 1 |
| Dyer, M | 1 |
| Atkinson, E | 1 |
| Jackson, E | 1 |
| Kundra, V | 1 |
| Kurzrock, R | 1 |
| Bast, RC | 1 |
| Mills, GB | 1 |
| Alberti, P | 1 |
| Spadaro, F | 1 |
| Ramoni, C | 1 |
| D'Ascenzo, S | 1 |
| Millimaggi, D | 1 |
| Pavan, A | 1 |
| Dolo, V | 1 |
| Spruss, T | 1 |
| Bernhardt, G | 1 |
| Schönenberger, H | 1 |
| Engel, J | 1 |
| Schwartz, BM | 1 |
| Hong, G | 1 |
| Morrison, BH | 1 |
| Wu, W | 1 |
| Baudhuin, LM | 1 |
| Xiao, YJ | 1 |
| Mok, SC | 1 |
| Xu, Y | 1 |
1 trial available for phosphorylcholine and Cancer of Ovary
| Article | Year |
|---|---|
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Su | 2012 |
11 other studies available for phosphorylcholine and Cancer of Ovary
| Article | Year |
|---|---|
DHRS2 inhibits cell growth and metastasis in ovarian cancer by downregulation of CHKα to disrupt choline metabolism.
Topics: Carbonyl Reductase (NADPH); Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cho | 2022 |
Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Cisplatin; Hu | 2013 |
Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chol | 2014 |
Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Resist | 2015 |
Evaluation of PolyMPC-Dox Prodrugs in a Human Ovarian Tumor Model.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Female; Humans; Maximum Tolerated Dos | 2016 |
Erucylphosphocholine shows a strong anti-growth activity in human endometrial and ovarian cancer cells.
Topics: Apoptosis; Caspase 9; Cell Cycle; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; Cycl | 2008 |
Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2011 |
Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Casp | 2011 |
Alterations of choline phospholipid metabolism in ovarian tumor progression.
Topics: Carbon Radioisotopes; Cell Line, Tumor; Choline; Choline Kinase; Disease Progression; Female; Humans | 2005 |
Antitumour activity of miltefosine alone and after combination with platinum complexes on MXT mouse mammary carcinoma models.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug | 1993 |
Lysophospholipids increase interleukin-8 expression in ovarian cancer cells.
Topics: Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Interleuki | 2001 |